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ABSTRACT 
 
Embryonic development is a process that involves a number of evolutionarily well-conserved signaling 
cascades, including the hedgehog pathway.  Mutations in components of this pathway have been identified in 
certain developmental disorders, and in many different kinds of cancers.  In fact, the most common cancer in the 
Western World, basal cell carcinoma (BCC) of the skin, is due to mutations that cause aberrantly activated 
hedgehog signaling.  This thesis focuses on a protein known as Suppressor of fused (Sufu), which is an essential 
tumor suppressor within the hedgehog pathway.  In PAPER I, we made the surprising observation that Sufu 
actually plays a fundamental role in the mammalian hedgehog signaling pathway, in contrast to its role in fruit 
flies and even zebrafish.  In these organisms, Sufu plays an insignificant part in normal hedgehog signaling, 
since its absence only results in minor phenotypic changes.  However, in the mouse, we showed that loss of 
Sufu leads to embryonic death in mid-gestation with the embryos exhibiting severe cephalic defects and an open 
neural tube.  We also demonstrated that the Sufu loss-of-function phenotype was due to ligand-independent 
activation of the hedgehog signaling pathway. 
In humans, Gorlin syndrome is a rare developmental disorder that in the majority of cases is due to 
inactivating mutations in the gene that encodes the hedgehog receptor, PTCH1.  This leads to overactivated 
hedgehog signaling, since PTCH1 is no longer able to inhibit the signal transducer, Smoothened (SMO).  Gorlin 
syndrome involves an array of different developmental defects, but it also leads to increased tumor 
susceptibility, especially in the form of multiple BCCs.  In PAPER I we discovered that mice, heterozygous for 
the Sufu gene, develop features of Gorlin syndrome, including a skin phenotype with BCC-like attributes, in 
addition to developmental aberrations in the form of jaw keratocysts.  In addition, we showed that the extent of 
epidermal skin changes correlated with increased hedgehog pathway activation. 
The BCC-like lesions in Sufu+/- mice are reminiscent of basaloid follicular hamartomas (BFH), 
which are more benign lesions than BCCs.  In PAPER II, the aim was to investigate whether the Sufu+/- skin 
lesions would develop into full-blown BCCs if Trp53 was knocked out simultaneously.  Trp53 is a well-known 
tumor suppressor gene that can enhance hedgehog-driven tumors, and is often mutated in sporadic BCCs, 
sometimes in combination with PTCH1 mutations.  We showed that Sufu+/- mice on a Trp53 null background 
develop medulloblastomas and rhabdomyosarcomas, which is consistent with previous reports.  Surprisingly, 
however, the Sufu+/- skin phenotype was not altered in the absence of Trp53, and showed no changes in latency, 
multiplicity, cellular phenotype or proliferative capacity during the lifespan of the mice.  This finding suggests a 
differential, tissue-specific sensitivity to Sufu and Trp53 gene loss, possibly linked to developmental phase and 
proliferative potential in specific tissues. 
In PAPER III, we studied developmental and differentiation processes in the absence of Sufu, using 
embryonic stem cells (ESCs) derived from Sufu-/- pre-implantation embryos.  Sufu-/- ESCs were found to express 
typical pluripotency markers, but the activity of the hedgehog pathway was increased only modestly compared 
to wild-type ESCs, as indicated by Gli1 target gene expression.  The Sufu-/- ESCs formed embryoid bodies in 
vitro, which, in later stages, were smaller than their wild-type counterparts, suggesting a deficiency in 
proliferation.  To test the differentiation capacity of the Sufu-/- ESCs in vivo, the cells were injected 
subcutaneously into nude mice to form teratomas.  Teratomas from Sufu-/- ESCs developed at efficiencies and 
latencies equivalent to teratomas from wild-type ESCs, yet in stark contrast to wild-type, Sufu-/- teratomas were 
dominated by neuroectodermal tissues and were deficient in the mesodermal derivatives, cartilage and bone.  
These findings call attention to the central role played by Sufu in the hedgehog signaling pathway, and propose a 
function for Sufu in ectodermal-mesodermal cell fate decision. 
In a PRELIMINARY STUDY, we have generated conditional Sufu mutant mice with the aim of 
deleting Sufu in specific tissues at specific time-points.  These studies are ongoing, and experiments to create 
mice with complete loss of Sufu in the K5 (basal cell) compartment of the skin have been initiated. 
In summary, the studies in this thesis highlight an essential role for Sufu in the hedgehog signaling 
pathway during development and tumorigenesis in mammals. 
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